Cargando…
Atezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? A review of efficacy, safety and place in therapy
Advanced non-small cell lung cancer (NSCLC) prognosis is still poor and has recently been reformed by the development of immune checkpoint inhibitors and the approval of anti-PD-1 (programmed cell-death 1) treatments such as nivolumab and pembrolizumab in second line. More recently, atezolizumab (MD...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808842/ https://www.ncbi.nlm.nih.gov/pubmed/29449897 http://dx.doi.org/10.1177/1758834017741074 |
_version_ | 1783299502949531648 |
---|---|
author | Jean, Fanny Tomasini, Pascale Barlesi, Fabrice |
author_facet | Jean, Fanny Tomasini, Pascale Barlesi, Fabrice |
author_sort | Jean, Fanny |
collection | PubMed |
description | Advanced non-small cell lung cancer (NSCLC) prognosis is still poor and has recently been reformed by the development of immune checkpoint inhibitors and the approval of anti-PD-1 (programmed cell-death 1) treatments such as nivolumab and pembrolizumab in second line. More recently, atezolizumab (MDPL 3280A), a programmed cell-death-ligand 1 (PD-L1) inhibitor, was also studied in this setting. Here, we report a review of the literature assessing the efficacy, safety, and place of atezolizumab in the second-line treatment of advanced NSCLC. We performed a literature search of PubMed, American Society of Clinical Oncology, European Society of Medical Oncology and World Conference on Lung Cancer meetings. Atezolizumab showed a good tolerance profile and efficacy in comparison with docetaxel for second-line treatment of advanced NSCLC. Potential predictive biomarkers also have to be assessed. |
format | Online Article Text |
id | pubmed-5808842 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-58088422018-02-15 Atezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? A review of efficacy, safety and place in therapy Jean, Fanny Tomasini, Pascale Barlesi, Fabrice Ther Adv Med Oncol Reviews Advanced non-small cell lung cancer (NSCLC) prognosis is still poor and has recently been reformed by the development of immune checkpoint inhibitors and the approval of anti-PD-1 (programmed cell-death 1) treatments such as nivolumab and pembrolizumab in second line. More recently, atezolizumab (MDPL 3280A), a programmed cell-death-ligand 1 (PD-L1) inhibitor, was also studied in this setting. Here, we report a review of the literature assessing the efficacy, safety, and place of atezolizumab in the second-line treatment of advanced NSCLC. We performed a literature search of PubMed, American Society of Clinical Oncology, European Society of Medical Oncology and World Conference on Lung Cancer meetings. Atezolizumab showed a good tolerance profile and efficacy in comparison with docetaxel for second-line treatment of advanced NSCLC. Potential predictive biomarkers also have to be assessed. SAGE Publications 2017-12-19 2017-12 /pmc/articles/PMC5808842/ /pubmed/29449897 http://dx.doi.org/10.1177/1758834017741074 Text en © The Author(s), 2017 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Reviews Jean, Fanny Tomasini, Pascale Barlesi, Fabrice Atezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? A review of efficacy, safety and place in therapy |
title | Atezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? A review of efficacy, safety and place in therapy |
title_full | Atezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? A review of efficacy, safety and place in therapy |
title_fullStr | Atezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? A review of efficacy, safety and place in therapy |
title_full_unstemmed | Atezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? A review of efficacy, safety and place in therapy |
title_short | Atezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? A review of efficacy, safety and place in therapy |
title_sort | atezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? a review of efficacy, safety and place in therapy |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808842/ https://www.ncbi.nlm.nih.gov/pubmed/29449897 http://dx.doi.org/10.1177/1758834017741074 |
work_keys_str_mv | AT jeanfanny atezolizumabfeasiblesecondlinetherapyforpatientswithnonsmallcelllungcancerareviewofefficacysafetyandplaceintherapy AT tomasinipascale atezolizumabfeasiblesecondlinetherapyforpatientswithnonsmallcelllungcancerareviewofefficacysafetyandplaceintherapy AT barlesifabrice atezolizumabfeasiblesecondlinetherapyforpatientswithnonsmallcelllungcancerareviewofefficacysafetyandplaceintherapy |